A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer.

Autor:	Loriot Y; Institut de Cancérologie Gustave Roussy, Villejuif, France., Kalebasty AR; University of California, Irvine, CA, USA., Fléchon A; Centre Léon Bérard, Lyon, France., Jain RK; H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA., Gupta S; Division of Oncology, Department of Medicine, University of Utah's Huntsman Cancer Institute, UT, USA., Bupathi M; Rocky Mountain Cancer Centers, Littleton, CO, USA., Beuzeboc P; Hôpital Foch, Suresnes, France., Palmbos P; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA., Balar AV; Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA., Kyriakopoulos CE; University of Wisconsin Carbone Cancer Center, Madison, WI, USA., Pouessel D; Institut Claudius Regaud/Cancer Comprehensive Center, IUCT, Oncopole, Toulouse, France., Sternberg CN; Weill Cornell Medicine, New York, NY, USA., Tonelli J; Gilead Sciences, Inc., Parsippany, NJ, USA., Sierecki M; Gilead Sciences, Inc., Parsippany, NJ, USA., Zhou H; Gilead Sciences, Inc., Parsippany, NJ, USA., Grivas P; Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA., Barthélémy P; Hôpitaux Universitaires de Strasbourg/Institut de Cancérologie Strasbourg Europe, Strasbourg, France., Bangs R; Patient Advocate, Pittsford, New York, NY, USA., Tagawa ST; Weill Cornell Medicine, New York, NY, USA.
Jazyk:	angličtina
Zdroj:	Future oncology (London, England) [Future Oncol] 2024; Vol. 20 (23), pp. 1621-1631. Date of Electronic Publication: 2024 Jun 05.
DOI:	10.2217/fon-2023-1030
Abstrakt:	What Is This Summary About?: Sacituzumab govitecan (brand name: TRODELVY ® ) is a new treatment being studied for people with a type of bladder cancer, called urothelial cancer, that has progressed to a locally advanced or metastatic stage. Locally advanced and metastatic urothelial cancer are usually treated with platinum-based chemotherapy. Metastatic urothelial cancer is also treated with immune checkpoint inhibitors. There are few treatment options for people whose cancer gets worse after receiving these treatments. Sacituzumab govitecan is a suitable treatment option for most people with urothelial cancer because it aims to deliver an anti-cancer drug directly to the cancer in an attempt to limit the potential harmful side effects on healthy cells. This is a summary of a clinical study called TROPHY-U-01, focusing on the first group of participants, referred to as Cohort 1. All participants in Cohort 1 received sacituzumab govitecan. What Are the Key Takeaways?: All participants received previous treatments for their metastatic urothelial cancer, including a platinum-based chemotherapy and a checkpoint inhibitor. The tumor in 31 of 113 participants became significantly smaller or could not be seen on scans after sacituzumab govitecan treatment; an effect that lasted for a median of 7.2 months. Half of the participants were still alive 5.4 months after starting treatment, without their tumor getting bigger or spreading further. Half of them were still alive 10.9 months after starting treatment regardless of tumor size changes. Most participants experienced side effects. These side effects included lower levels of certain types of blood cells, sometimes with a fever, and loose or watery stools (diarrhea). Side effects led 7 of 113 participants to stop taking sacituzumab govitecan. What Were the Main Conclusions Reported by the Researchers?: The study showed that sacituzumab govitecan had significant anti-cancer activity. Though most participants who received sacituzumab govitecan experienced side effects, these did not usually stop participants from continuing sacituzumab govitecan. Doctors can help control these side effects using treatment guidelines, but these side effects can be serious. Clinical Trial Registration : NCT03547973 (ClinicalTrials.gov) (TROPHY-U-1).
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu